CONMED Q3 revenue up 6.7% to $338M; adjusted EPS $1.08; suspends dividend, authorizes $150M buyback

CONMED Corp

2025-Q3 EPS reported $0.97 revenue$1,001,526,000

Diluted GAAP EPS $0.09 vs $1.57 YoY due to $19.7M product rationalization and $9.2M consulting costs.
Adjusted diluted EPS $1.08 vs $1.05 YoY; full-year adjusted EPS guidance raised to $4.48-$4.53.
Full-year revenue guidance narrowed to $1.365B-$1.372B; tariffs expected to reduce Q4 EPS by ~$0.07.
Board authorized $150M share repurchase program; quarterly cash dividend suspended; at least $25M annual buybacks from 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.